Ajay Gogia
| Grant Category: | Fulbright-Nehru Academic & Professional Excellence Award (Research) |
| Project Title: | Impact of Carboplatin/PARP inhibitor in BRCA associated breast cancer |
| Field of Study: | Public Health |
| Home Institution: | All India Institute of Medical Sciences, New Delhi, Delhi |
| Host Institution: | Cleveland Clinic , Cleveland, OH |
| Grant Start Month: | March 2025 |
| Duration of Grant: | Four months |
Brief Bio:
Dr Ajay Gogia is an Additional Professor in the Department of Medical Oncology at All India Institute of Medical Sciences. He received his M.B.B.S, M.D. (Internal Medicine) degree from Banaras Hindu University, D.M. (Medical Oncology) from AIIMS, New Delhi.
He has over 17 years of working and teaching experience in Medical Oncology and specializes in Breast Cancer and Non-Hodgkin’s Lymphoma. His research is well published with more than 400 peer-reviewed articles in National and International oncology journals He has received the Dronacharya Award for his excellence from the Health Minister of India.
Dr. Ajay Gogia’s Fulbright-Nehru project aims to understand the molecular pathogenesis of triple-negative breast cancer (TNBC) and see the impact of Carboplatin and /or PARP inhibitor with standard dose-dense neoadjuvant chemotherapy on BRCA-associated triple-negative breast cancer. The precise stratification of TNBC is crucial for the development of potent standardized and targeted therapies, as it has a very poor prognosis. BRCA mutational status is the only clinically validated biomarker for personalized therapy in TNBC.